Diabetes PubMed

  • Increase font size
  • Default font size
  • Decrease font size
Home Medication Insulin Subcutaneous Successful treatment of severe subcutaneous insulin resistance with inhaled insulin therapy

Successful treatment of severe subcutaneous insulin resistance with inhaled insulin therapy

Pediatr Diabetes. 2009 Sep 16.

van Alfen-van der Velden AA, Noordam C, de Galan BE, Hoorweg-Nijman JJ, Voorhoeve PG, Westerlaken C.

Metabolic and Endocrine Diseases at the Department of Pediatrics, Radboud University Medical Centre, Nijmegen, The Netherlands.

van Alfen-van der Velden AAEM, Noordam C, de Galan BE, Hoorweg-Nijman JJG, Voorhoeve PG, Westerlaken C. Successful treatment of severe subcutaneous insulin resistance with inhaled insulin therapy. The potential of inhaled insulin therapy for severe resistance to subcutaneous insulin was tested in a 7-yr old boy with type 1 diabetes mellitus. The efficiency of 1 mg inhaled insulin (Exubera((R))) was examined by a 4-h euglycemic clamp study. During the clamp, the glucose infusion rate started to increase 25 min after inhalation and peaked 120 min after inhalation. Subsequently, a trial of inhaled insulin monotherapy was initiated consisting of pre-meal inhalations and one inhalation during the night. Since glycemic control remained fair (HbA1c approximately 8.5%), this therapy was continued. Over the ensuing 18 months, mild keto-acidosis occurred twice during gastro-enteritis. Inhaled insulin was well tolerated and pulmonary function did not deteriorate. We conclude that severe resistance to subcutaneous insulin does not preclude sufficient absorption of insulin delivered by pulmonary.

PMID: 19761527

 

Bookmark and Share

Popular Diabetes PubMed Citations

Newsflash

Millions unite for diabetes awareness on World Diabetes Day 2010
Starting today, people from all corners of the world are uniting together for three days of celebration to put diabetes firmly in the public spotlight. World Diabetes Day is the best opportunity there is to draw attention to the silent killer that is diabetes.
 
Bristol-Myers Squibb Foundation Launches $100 Million Initiative
The Bristol-Myers Squibb Foundation announced Together on Diabetes®: Communities Uniting to Meet America's Diabetes Challenge, a 5-year, $100 million initiative to help patients living with type 2 diabetes better manage their disease beyond the doors of their doctor's office - in their homes and communities - and for the course of their disease.
 
New global survey reveals more than one in three patients fail to take insulin as prescribed
More than one in three diabetes patients skip doses or fail to take their insulin as prescribed, stating that they have done so on average three times in the last month, and 77% of physicians estimate that in reality this number could be as high as six doses*, according to the Global Attitudes of Patients and Physicians in Insulin Therapy (GAPPTM) survey, released today by Novo Nordisk.
 

Facebook Page Twitter Subscribe to Latest Diabetes PubMed facts... by Email RSS

Subscribe

Get Diabetes PubMed facts delivered by email. Enter your email address:


Delivered by FeedBurner

Who's Online

We have 6 guests online

Sponsored Links

PharmaNews.eu
PharmaNews.eu - the dynamic European pharmaceutical news engine.
www.pharmanews.eu

Advertise here